{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:46:12Z","timestamp":1781624772838,"version":"3.54.5"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s11912-021-01079-x","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T15:03:11Z","timestamp":1623682991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["The Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3773-7060","authenticated-orcid":false,"given":"Laura M.","family":"Chambers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker","family":"Bussies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Esakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Reizes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Michener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"issue":"4","key":"1079_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nm.4517","volume":"24","author":"JA Gilbert","year":"2018","unstructured":"Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current understanding of the human microbiome. Nat Med. 2018;24(4):392\u2013400 Excellent review summarizing the current data for the human microbiome and impact on human health.","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"1079_CR2","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1073\/pnas.1002611107","volume":"108 Suppl 1","author":"J Ravel","year":"2011","unstructured":"Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108 Suppl 1(Suppl 1):4680\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1079_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nri.2016.42","volume":"16","author":"MG Rooks","year":"2016","unstructured":"Rooks MG, Garrett WS. Gut microbiota, metabolites, and host immunity. Nat Rev Immunol. 2016;16(6):341\u201352.","journal-title":"Nat Rev Immunol"},{"issue":"7402","key":"1079_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature11234","volume":"486","author":"Human Microbiome Project Consortium","year":"2012","unstructured":"Human Microbiome Project Consortium. Structure, function, and diversity of the healthy human microbiome. Nature. 2012;486(7402):207\u201314.","journal-title":"Nature."},{"issue":"5778","key":"1079_CR5","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.1124234","volume":"312","author":"SR Gill","year":"2006","unstructured":"Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312(5778):1355\u20139.","journal-title":"Science."},{"issue":"2","key":"1079_CR6","doi-asserted-by":"publisher","first-page":"154.e1","DOI":"10.1016\/j.ajog.2019.08.011","volume":"222","author":"YM Komesu","year":"2020","unstructured":"Komesu YM, Dinwiddie DL, Richter HE, Lukacz ES, Sung VW, Siddiqui NY, et al. Defining the relationship between vaginal and urinary microbiomes. Am J Obstet Gynecol. 2020;222(2):154.e1\u2013154.e10.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"1079_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13073-016-0368-y","volume":"8","author":"A Hokenstad","year":"2016","unstructured":"Hokenstad A, Distad TJ, Cheek EH, Keeney GL, Creedon DJ, Nelson H, et al. Potential contribution of the uterine microbiome in the development of endometrial cancer. Genome Med. 2016;8(1):122 This study characterizes the microbiome of the female genital tract in women with uterine cancer compared to those with benign pathology.","journal-title":"Genome Med"},{"key":"1079_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3389\/fimmu.2018.00208","volume":"9","author":"JM Baker","year":"2018","unstructured":"Baker JM, Chase DM, Herbst-Kralovetz MM. Uterine microbiota: residents, tourists, or invaders? Front Immunol. 2018;9:208.","journal-title":"Front Immunol"},{"issue":"22","key":"1079_CR9","doi-asserted-by":"publisher","first-page":"36225","DOI":"10.18632\/oncotarget.16717","volume":"8","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Tian T, Wei Z, Shih N, Feldman MD, Alwine JC, et al. The ovarian cancer oncobiome. Oncotarget. 2017;8(22):36225\u201345 This study utilizes next-generation sequencing to characterize the bacterial, fungal, and viral signatures within ovarian cancer tissues compared to controls.","journal-title":"Oncotarget"},{"key":"1079_CR10","doi-asserted-by":"crossref","unstructured":"Miao R, Badger TC, Groesch K, Diaz-Sylvester PL, Wilson T, Ghareeb A, et al. Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer. PLoS One. 2020;15(1).","DOI":"10.1371\/journal.pone.0227707"},{"issue":"1","key":"1079_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41467-017-00901-0","volume":"8","author":"C Chen","year":"2017","unstructured":"Chen C, Song X, Wei W, Zhong H, Dai J, Lan Z, et al. The microbiota continuum along the female reproductive tract and its relation to uterine-related diseases. Nat Commun. 2017;8(1):875 Important study that examined the microbiota at six sites along the female reproductive tract using 16s rRNA sequencing, providing insight into the unique microorganisms present.","journal-title":"Nat Commun"},{"issue":"3","key":"1079_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.fertnstert.2016.11.028","volume":"107","author":"SM Miles","year":"2017","unstructured":"Miles SM, Hardy BL, Merrell DS. Investigation of the microbiota of the reproductive tract in women undergoing a total hysterectomy and bilateral salpingo-oophorectomy. Fertil Steril. 2017;107(3):813\u201320.","journal-title":"Fertil Steril"},{"key":"1079_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.maturitas.2017.06.025","volume":"103","author":"JM Baker","year":"2017","unstructured":"Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017;103:45\u201353 Excellent review article which summarizes the evidence for the estrobolome, or the gut microbiome-estrogen axis.","journal-title":"Maturitas"},{"issue":"1","key":"1079_CR14","doi-asserted-by":"publisher","first-page":"19213","DOI":"10.1038\/s41598-019-55720-8","volume":"9","author":"DM Walsh","year":"2019","unstructured":"Walsh DM, Hokenstad AN, Chen J, Sung J, Jenkins GD, Chia N, et al. Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome). Sci Rep. 2019;9(1):19213 Important study that correlated the presence of a specific bacteria, Porphyromonas somerae, within the female reproductive tract with the development of endometrial cancer.","journal-title":"Sci Rep"},{"issue":"7484","key":"1079_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12820","volume":"505","author":"LA David","year":"2014","unstructured":"David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559\u201363.","journal-title":"Nature."},{"issue":"3","key":"1079_CR16","doi-asserted-by":"publisher","first-page":"e92193","DOI":"10.1371\/journal.pone.0092193","volume":"9","author":"CC Evans","year":"2014","unstructured":"Evans CC, LePard KJ, Kwak JW, Stancukas MC, Laskowski S, Dougherty J, et al. Exercise prevents weight gain and alters the gut microbiota in a mouse model of high fat diet-induced obesity. PLoS One. 2014;9(3):e92193.","journal-title":"PLoS One"},{"issue":"1","key":"1079_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajog.2018.12.011","volume":"221","author":"N Brusselaers","year":"2019","unstructured":"Brusselaers N, Shrestha S, van de Wijgert J, Verstraelen H. Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. Am J Obstet Gynecol. 2019;221(1):9\u201318 Comprehensive meta-analysis of high-quality studies supporting an association with vaginal microbiome dysbiosis, HPV persistence, and development of invasive cervical carcinoma.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"1079_CR18","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ajog.2018.11.1089","volume":"220","author":"S Greenbaum","year":"2019","unstructured":"Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub AY. Ecological dynamics of the vaginal microbiome in relation to health and disease. Am J Obstet Gynecol. 2019;220(4):324\u201335.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1079_CR19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.fertnstert.2018.06.036","volume":"110","author":"SJ Kroon","year":"2018","unstructured":"Kroon SJ, Ravel J, Huston WM. Cervicovaginal microbiota, women\u2019s health, and reproductive outcomes. Fertil Steril. 2018;110(3):327\u201336.","journal-title":"Fertil Steril"},{"issue":"4","key":"1079_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41585-020-0286-z","volume":"17","author":"P \u0141aniewski","year":"2020","unstructured":"\u0141aniewski P, Ilhan ZE, Herbst-Kralovetz MM. The microbiome and gynaecological cancer development, prevention, and therapy. Nat Rev Urol. 2020;17(4):232\u201350 Comprehensive review summarizing the association between the microbiota of the female reproductive tract and gynecologic cancers.","journal-title":"Nat Rev Urol"},{"issue":"9","key":"1079_CR21","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1111\/jog.13701","volume":"44","author":"I Mert","year":"2018","unstructured":"Mert I, Walther-Antonio M, Mariani A. Case for a role of the microbiome in gynecologic cancers: clinician\u2019s perspective. J Obstet Gynaecol Res. 2018;44(9):1693\u2013704.","journal-title":"J Obstet Gynaecol Res"},{"issue":"4","key":"1079_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/AOG.0000000000004052","volume":"136","author":"SES Jeney","year":"2020","unstructured":"Jeney SES, Lane F, Oliver A, Whiteson K, Dutta S. Fecal Microbiota transplantation for the treatment of refractory recurrent urinary tract infection. Obstet Gynecol. 2020;136(4):771\u20133.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"1079_CR23","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/s41467-020-15856-y","volume":"11","author":"A Mitra","year":"2020","unstructured":"Mitra A, MacIntyre DA, Ntritsos G, Smith A, Tsilidis KK, Marchesi JR, et al. The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions. Nat Commun. 2020;11(1):1999 Important study demonstrating a link between vaginal microbiota, including non-Lactobacillus-dominant species, and regression of high-grade cervical dysplasia.","journal-title":"Nat Commun"},{"issue":"2","key":"1079_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/1471-0528.15854","volume":"127","author":"J Norenhag","year":"2020","unstructured":"Norenhag J, Du J, Olovsson M, Verstraelen H, Engstrand L, Brusselaers N. The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. BJOG. 2020;127(2):171\u201380 Comprehensive meta-analysis of high-quality studies supporting an association with vaginal microbiome dysbiosis, HPV persistence, and development of invasive cervical carcinoma.","journal-title":"BJOG"},{"issue":"3","key":"1079_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/1471-0528.14631","volume":"125","author":"M Champer","year":"2018","unstructured":"Champer M, Wong AM, Champer J, Brito IL, Messer PW, Hou JY, et al. The role of the vaginal microbiome in gynaecological cancer. BJOG. 2018;125(3):309\u201315.","journal-title":"BJOG."},{"issue":"1","key":"1079_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/microorganisms7010014","volume":"7","author":"E Rinninella","year":"2019","unstructured":"Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14 Helpful review summarizing data for environmental factors that influence the gut microbiome and how this impacts disease states.","journal-title":"Microorganisms"},{"issue":"7346","key":"1079_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/nature09944","volume":"473","author":"M Arumugam","year":"2011","unstructured":"Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174\u201380.","journal-title":"Nature."},{"issue":"1","key":"1079_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1940-6207.CAPR-18-0233","volume":"12","author":"W Ritu","year":"2019","unstructured":"Ritu W, Enqi W, Zheng S, Wang J, Ling Y, Wang Y. Evaluation of the associations between cervical microbiota and HPV infection, clearance, and persistence in cytologically normal women. Cancer Prev Res (Phila). 2019;12(1):43\u201356.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1","key":"1079_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1186\/s12879-020-05324-9","volume":"20","author":"Y Chen","year":"2020","unstructured":"Chen Y, Qiu X, Wang W, Li D, Wu A, Hong Z, et al. Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort. BMC Infect Dis. 2020;20(1):629.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"1079_CR30","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/infdis\/jiu330","volume":"210","author":"RM Brotman","year":"2014","unstructured":"Brotman RM, Shardell MD, Gajer P, Tracy JK, Zenilman JM, Ravel J, et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis. 2014;210(11):1723\u201333.","journal-title":"J Infect Dis"},{"issue":"1","key":"1079_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1017\/S0950268815000965","volume":"144","author":"EO Dareng","year":"2016","unstructured":"Dareng EO, Ma B, Famooto AO, Adebamowo SN, Offiong RA, Olaniyan O, et al. Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women. Epidemiol Infect. 2016;144(1):123\u201337.","journal-title":"Epidemiol Infect"},{"key":"1079_CR32","doi-asserted-by":"crossref","unstructured":"Lee JE, Lee S, Lee H, Song YM, Lee K, Han MJ, et al. Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort. PLoS One. 2013;8(5).","DOI":"10.1371\/journal.pone.0063514"},{"key":"1079_CR33","doi-asserted-by":"crossref","unstructured":"So KA, Yang EJ, Kim NR, Hong SR, Lee JH, Hwang CS, et al. Changes of vaginal microbiota during cervical carcinogenesis in women with human papillomavirus infection. PLoS One. 2020;15(9) Evaluates specific changes in the vaginal microbiota during cervical carcinogenesis and identifies that decreased Lactobacillus crispatus and anaerobic bacteria were associated with invasive cervical cancer.","DOI":"10.1371\/journal.pone.0238705"},{"issue":"1","key":"1079_CR34","doi-asserted-by":"publisher","first-page":"9905","DOI":"10.1038\/s41598-019-46173-0","volume":"9","author":"AD Winters","year":"2019","unstructured":"Winters AD, Romero R, Gervasi MT, Gomez-Lopez N, Tran MR, Garcia-Flores V, et al. Does the endometrial cavity have a molecular microbial signature? Sci Rep. 2019;9(1):9905.","journal-title":"Sci Rep"},{"issue":"4","key":"1079_CR35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/biom10040593","volume":"10","author":"NM Molina","year":"2020","unstructured":"Molina NM, Sola-Leyva A, Saez-Lara MJ, Plaza-Diaz J, Tubi\u0107-Pavlovi\u0107 A, Romero B, et al. New opportunities for endometrial health by modifying uterine microbial composition: present or future? Biomolecules. 2020;10(4):593.","journal-title":"Biomolecules."},{"issue":"4","key":"1079_CR36","first-page":"1170","volume":"10","author":"YC Chou","year":"2020","unstructured":"Chou YC, Ho PY, Chen WJ, Wu SH, Pan MH. Lactobacillus fermentum V3 ameliorates colitis-associated tumorigenesis by modulating the gut microbiome. Am J Cancer Res. 2020;10(4):1170\u201381.","journal-title":"Am J Cancer Res"},{"issue":"5","key":"1079_CR37","doi-asserted-by":"publisher","first-page":"316","DOI":"10.5455\/medarh.2019.73.316-320","volume":"73","author":"S Bajramagic","year":"2019","unstructured":"Bajramagic S, Hodzic E, Mulabdic A, Holjan S, Smajlovic SV, Rovcanin A. Usage of probiotics and its clinical significance at surgically treated patients suffering from colorectal carcinoma. Med Arch. 2019;73(5):316\u201320.","journal-title":"Med Arch"},{"key":"1079_CR38","doi-asserted-by":"crossref","unstructured":"Kotzampassi K, Stavrou G, Damoraki G, Georgitsi M, Basdanis G, Tsaousi G, et al. A Four-probiotics regimen reduces postoperative complications after colorectal surgery: a randomized, double-blind, placebo-controlled study. World J Surg. 2015;39(11):2776\u201383.","DOI":"10.1007\/s00268-015-3071-z"},{"issue":"6230","key":"1079_CR39","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.aaa4972","volume":"348","author":"WS Garrett","year":"2015","unstructured":"Garrett WS. Cancer and the microbiota. Science. 2015;348(6230):80\u20136.","journal-title":"Science."},{"key":"1079_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3389\/fonc.2020.00163","volume":"10","author":"H Cheng","year":"2020","unstructured":"Cheng H, Wang Z, Cui L, Wen Y, Chen X, Gong F, et al. Opportunities and challenges of the human microbiome in ovarian cancer. Front Oncol. 2020;10:163.","journal-title":"Front Oncol"},{"key":"1079_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1479-5876-10-253","volume":"10","author":"R Flores","year":"2012","unstructured":"Flores R, Shi J, Fuhrman B, Xu X, Veenstra TD, Gail MH, et al. Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study. J Transl Med. 2012;10:253.","journal-title":"J Transl Med"},{"issue":"1","key":"1079_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"29","key":"1079_CR43","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1200\/JCO.20.00549","volume":"38","author":"A Le\u00f3n-Castillo","year":"2020","unstructured":"Le\u00f3n-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38(29):3388\u201397.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1079_CR44","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.fertnstert.2007.03.074","volume":"89","author":"E Cicinelli","year":"2008","unstructured":"Cicinelli E, De Ziegler D, Nicoletti R, Colafiglio G, Saliani N, Resta L, et al. Chronic endometritis: correlation among hysteroscopic, histologic, and bacteriologic findings in a prospective trial with 2190 consecutive office hysteroscopies. Fertil Steril. 2008;89(3):677\u201384.","journal-title":"Fertil Steril"},{"issue":"4","key":"1079_CR45","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1677\/ERC-10-0053","volume":"17","author":"L Dossus","year":"2010","unstructured":"Dossus L, Rinaldi S, Becker S, Lukanova A, Tjonneland A, Olsen A, et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer. 2010;17(4):1007\u201319.","journal-title":"Endocr Relat Cancer"},{"issue":"34","key":"1079_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001278","volume":"94","author":"TK Yang","year":"2015","unstructured":"Yang TK, Chung CJ, Chung SD, Muo CH, Chang CH, Huang CY. Risk of endometrial cancer in women with pelvic inflammatory disease: a nationwide population-based retrospective cohort study. Medicine (Baltimore). 2015;94(34):e1278.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"1079_CR47","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1093\/infdis\/jiu004","volume":"209","author":"SY Doerflinger","year":"2014","unstructured":"Doerflinger SY, Throop AL, Herbst-Kralovetz MM. Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner. J Infect Dis. 2014;209(12):1989\u201399.","journal-title":"J Infect Dis"},{"issue":"6","key":"1079_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4143\/crt.2005.37.6.319","volume":"37","author":"EK Yim","year":"2005","unstructured":"Yim EK, Park JS. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005;37(6):319\u201324.","journal-title":"Cancer Res Treat"},{"key":"1079_CR49","doi-asserted-by":"crossref","unstructured":"Yoo W, Kim S, Huh WK, Dilley S, Coughlin SS, Partridge EE, et al. Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS One. 2017;12(2).","DOI":"10.1371\/journal.pone.0172548"},{"issue":"1","key":"1079_CR50","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/s41598-019-43849-5","volume":"9","author":"P \u0141aniewski","year":"2019","unstructured":"\u0141aniewski P, Cui H, Roe DJ, Barnes D, Goulder A, Monk BJ, et al. Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis. Sci Rep. 2019;9(1):7333 Demonstrates that specific cervicovaginal microbiota compositions are correlated with HPV persistence and development of invasive cervical cancer.","journal-title":"Sci Rep"},{"issue":"8","key":"1079_CR51","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1258\/ijsa.2012.011342","volume":"23","author":"YL Guo","year":"2012","unstructured":"Guo YL, You K, Qiao J, Zhao YM, Geng L. Bacterial vaginosis is conducive to the persistence of HPV infection. Int J STD AIDS. 2012;23(8):581\u20134.","journal-title":"Int J STD AIDS"},{"key":"1079_CR52","doi-asserted-by":"crossref","unstructured":"Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. PLoS Pathog. 2020;16(3).","DOI":"10.1371\/journal.ppat.1008376"},{"issue":"1","key":"1079_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/ijgc-2018-000032","volume":"29","author":"XP Chao","year":"2019","unstructured":"Chao XP, Sun TT, Wang S, Fan QB, Shi HH, Zhu L, et al. Correlation between the diversity of vaginal microbiota and the risk of high-risk human papillomavirus infection. Int J Gynecol Cancer. 2019;29(1):28\u201334.","journal-title":"Int J Gynecol Cancer"},{"key":"1079_CR54","doi-asserted-by":"publisher","first-page":"16865","DOI":"10.1038\/srep16865","volume":"5","author":"A Mitra","year":"2015","unstructured":"Mitra A, MacIntyre DA, Lee YS, Smith A, Marchesi JR, Lehne B, et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep. 2015;5:16865.","journal-title":"Sci Rep"},{"key":"1079_CR55","doi-asserted-by":"crossref","unstructured":"Audirac-Chalifour A, Torres-Poveda K, Bahena-Rom\u00e1n M, T\u00e9llez-Sosa J, Mart\u00ednez-Barnetche J, Cortina-Ceballos B, et al. Cervical microbiome and cytokine profile at various stages of cervical cancer: a pilot study. PLoS One. 2016;11(4) Important study which correlates type of vaginal microbiota with the risk of cervical neoplasia and invasive cancer and investigates inflammatory cytokine profiles.","DOI":"10.1371\/journal.pone.0153274"},{"issue":"1","key":"1079_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12905-019-0727-0","volume":"19","author":"J Wiik","year":"2019","unstructured":"Wiik J, Sengpiel V, Kyrgiou M, Nilsson S, Mitra A, Tanbo T, et al. Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study. BMC Womens Health. 2019;19(1):30.","journal-title":"BMC Womens Health"},{"key":"1079_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2334-11-10","volume":"11","author":"E Gillet","year":"2011","unstructured":"Gillet E, Meys JF, Verstraelen H, Bosire C, De Sutter P, Temmerman M, et al. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. BMC Infect Dis. 2011;11:10.","journal-title":"BMC Infect Dis"},{"key":"1079_CR58","doi-asserted-by":"publisher","first-page":"569022","DOI":"10.3389\/fcimb.2020.569022","volume":"10","author":"AB Moscicki","year":"2020","unstructured":"Moscicki AB, Shi B, Huang H, Barnard E, Li H. Cervical-vaginal microbiome and associated cytokine profiles in a prospective study of HPV 16 acquisition, persistence, and clearance. Front Cell Infect Microbiol. 2020;10:569022.","journal-title":"Front Cell Infect Microbiol"},{"key":"1079_CR59","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.ebiom.2019.04.028","volume":"44","author":"ZE Ilhan","year":"2019","unstructured":"Ilhan ZE, \u0141aniewski P, Thomas N, Roe DJ, Chase DM, Herbst-Kralovetz MM. Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling. EBioMedicine. 2019;44:675\u201390.","journal-title":"EBioMedicine."},{"issue":"2","key":"1079_CR60","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12602-017-9339-x","volume":"10","author":"KD Wang","year":"2018","unstructured":"Wang KD, Xu DJ, Wang BY, Yan DH, Lv Z, Su JR. Inhibitory effect of vaginal lactobacillus supernatants on cervical cancer cells. Probiotics Antimicrob Proteins. 2018;10(2):236\u201342.","journal-title":"Probiotics Antimicrob Proteins"},{"issue":"2","key":"1079_CR61","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/1471-0528.15981","volume":"127","author":"JC Borgogna","year":"2020","unstructured":"Borgogna JC, Shardell MD, Santori EK, Nelson TM, Rath JM, Glover ED, et al. The vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women: a cross-sectional analysis. BJOG. 2020;127(2):182\u201392 Investigates the vaginal metabolome, or the metabolic byproducts of each type of vaginal microbiota and correlates with HPV persistence or clearance.","journal-title":"BJOG"},{"issue":"2","key":"1079_CR62","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ygyno.2019.09.002","volume":"155","author":"TT Sims","year":"2019","unstructured":"Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, et al. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol. 2019;155(2):237\u201344.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1079_CR63","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13568-019-0763-z","volume":"9","author":"Z Wang","year":"2019","unstructured":"Wang Z, Wang Q, Zhao J, Gong L, Zhang Y, Wang X, et al. Altered diversity and composition of the gut microbiome in patients with cervical cancer. AMB Express. 2019;9(1):40.","journal-title":"AMB Express"},{"issue":"9","key":"1079_CR64","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s10096-012-1570-5","volume":"31","author":"S Shanmughapriya","year":"2012","unstructured":"Shanmughapriya S, Senthilkumar G, Vinodhini K, Das BC, Vasanthi N, Natarajaseenivasan K. Viral and bacterial aetiologies of epithelial ovarian cancer. Eur J Clin Microbiol Infect Dis. 2012;31(9):2311\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"8","key":"1079_CR65","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/ijc.32999","volume":"147","author":"A Idahl","year":"2020","unstructured":"Idahl A, Le Cornet C, Gonz\u00e1lez Maldonado S, Waterboer T, Bender N, Tj\u00f8nneland A, et al. Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: results from the EPIC cohort. Int J Cancer. 2020;147(8):2042\u201352.","journal-title":"Int J Cancer"},{"issue":"2","key":"1079_CR66","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ygyno.2020.02.028","volume":"157","author":"CP Chang","year":"2020","unstructured":"Chang CP, Chen Y, Blackburn B, Abdelaziz S, Rowe K, Snyder J, et al. Genitourinary disease risks among ovarian cancer survivors in a population-based cohort study. Gynecol Oncol. 2020;157(2):529\u201335.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1079_CR67","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ygyno.2020.02.002","volume":"157","author":"J Piao","year":"2020","unstructured":"Piao J, Lee EJ, Lee M. Association between pelvic inflammatory disease and risk of ovarian cancer: an updated meta-analysis. Gynecol Oncol. 2020;157(2):542\u20138.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1079_CR68","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ygyno.2016.08.318","volume":"143","author":"CB Rasmussen","year":"2016","unstructured":"Rasmussen CB, Jensen A, Albieri V, Andersen KK, Kjaer SK. Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: a nationwide population-based cohort study. Gynecol Oncol. 2016;143(2):346\u201351.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1079_CR69","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41416-019-0422-9","volume":"120","author":"RT Fortner","year":"2019","unstructured":"Fortner RT, Terry KL, Bender N, Brenner N, Hufnagel K, Butt J, et al. Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses\u2019 Health Studies. Br J Cancer. 2019;120(8):855\u201360.","journal-title":"Br J Cancer"},{"issue":"1","key":"1079_CR70","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41598-018-38031-2","volume":"9","author":"B Zhou","year":"2019","unstructured":"Zhou B, Sun C, Huang J, Xia M, Guo E, Li N, et al. The biodiversity composition of microbiome in ovarian carcinoma patients. Sci Rep. 2019;9(1):1691 High-throughput sequencing was performed to characterize the microbial signature of ovarian cancer tissues compared to controls.","journal-title":"Sci Rep"},{"issue":"5","key":"1079_CR71","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3390\/cancers12051309","volume":"12","author":"SI Kim","year":"2020","unstructured":"Kim SI, Kang N, Leem S, Yang J, Jo H, Lee M, et al. Metagenomic analysis of serum microbe-derived extracellular vesicles and diagnostic models to differentiate ovarian cancer and benign ovarian tumor. Cancers (Basel). 2020;12(5):1309.","journal-title":"Cancers (Basel)"},{"key":"1079_CR72","doi-asserted-by":"crossref","unstructured":"Xu S, Liu Z, Lv M, Chen Y, Liu Y. Intestinal dysbiosis promotes epithelial-mesenchymal transition by activating tumor-associated macrophages in ovarian cancer. Pathog Dis. 2019;77(2).","DOI":"10.1093\/femspd\/ftz019"},{"issue":"8","key":"1079_CR73","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S1470-2045(19)30340-7","volume":"20","author":"NR Nen\u00e9","year":"2019","unstructured":"Nen\u00e9 NR, Reisel D, Leimbach A, Franchi D, Jones A, Evans I, et al. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. Lancet Oncol. 2019;20(8):1171\u201382.","journal-title":"Lancet Oncol"},{"key":"1079_CR74","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3389\/fmicb.2019.01746","volume":"10","author":"G Mori","year":"2019","unstructured":"Mori G, Orena BS, Cultrera I, Barbieri G, Albertini AM, Ranzani GN, et al. Gut microbiota analysis in postoperative lynch syndrome patients. Front Microbiol. 2019;10:1746.","journal-title":"Front Microbiol"},{"issue":"6161","key":"1079_CR75","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1126\/science.1240527","volume":"342","author":"N Iida","year":"2013","unstructured":"Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967\u201370.","journal-title":"Science."},{"issue":"6","key":"1079_CR76","doi-asserted-by":"publisher","first-page":"e1150399","DOI":"10.1080\/2162402X.2016.1150399","volume":"5","author":"N Pflug","year":"2016","unstructured":"Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L, et al. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. Oncoimmunology. 2016;5(6):e1150399 Pre-clinical model of lymphoma, which demonstrated reduced efficacy of cisplatin in mice treated with antibiotics.","journal-title":"Oncoimmunology"},{"issue":"6371","key":"1079_CR77","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137.","journal-title":"Science."},{"issue":"6161","key":"1079_CR78","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1126\/science.1240537","volume":"342","author":"S Viaud","year":"2013","unstructured":"Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971\u20136.","journal-title":"Science."},{"key":"1079_CR79","doi-asserted-by":"crossref","unstructured":"Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019; Large retrospective cohort study in patients with melanomas and non-small cell lung carcinomas which demonstrated that antibiotic use before immunotherapy is associated with reduced drug efficacy and decreased survival.","DOI":"10.1001\/jamaoncol.2019.2785"},{"issue":"6371","key":"1079_CR80","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97\u2013103.","journal-title":"Science."},{"key":"1079_CR81","doi-asserted-by":"crossref","unstructured":"Abdel-Rahman O, Ghosh S, Walker J. Outcomes of metastatic colorectal cancer patients in relationship to prior and concurrent antibiotics use; individual patient data analysis of three clinical trials. Clin Transl Oncol. 2020.","DOI":"10.1007\/s12094-020-02301-1"},{"key":"1079_CR82","doi-asserted-by":"crossref","unstructured":"Chambers LM, Esakov EL, Braley C, Sangwan N, Vargas R, Rose PG, Lathia JD, Michener CM, Reizes O. Cisplatin chemotherapy impacts the gut microbiome in a pre-clinical murine model of epithelial ovarian cancer. Presented as a virtual poster at the Society of Gynecologic Oncology Virtual Meeting in March 2020.","DOI":"10.1016\/j.ygyno.2020.05.112"},{"key":"1079_CR83","doi-asserted-by":"crossref","unstructured":"Chambers LM, Esakov EL, Braley C, Sangwan N, Vargas R, Rose PG, Lathia JL, Michener CM, Reizes O. The gut microbiome attenuates epithelial ovarian cancer growth and platinum sensitivity. Novel opportunities for ovarian cancer treatment. Presented as a virtual poster at the Society of Gynecologic Oncology Virtual Meeting in March 2020.","DOI":"10.1016\/j.ygyno.2020.05.113"},{"issue":"20","key":"1079_CR84","first-page":"33903","volume":"S0090-8258","author":"LM Chambers","year":"2020","unstructured":"Chambers LM, Kuznicki M, Yao M, Chichura A, Gruner M, Reizes O, et al. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. Gynecol Oncol. 2020;S0090-8258(20):33903\u20132 Large retrospective cohort study in women with advanced ovarian cancer which demonstrated that antibiotic use during first-line platinum chemotherapy is associated with reduced progression-free survival and overall survival.","journal-title":"Gynecol Oncol"},{"key":"1079_CR85","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","volume":"20","author":"V Makker","year":"2019","unstructured":"Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:711\u20138.","journal-title":"Lancet Oncol"},{"key":"1079_CR86","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","volume":"35","author":"PA Ott","year":"2017","unstructured":"Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, et al. Safety and Antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J.Clin.Oncol. 2017;35:2535\u201341.","journal-title":"J.Clin.Oncol."},{"key":"1079_CR87","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.18.01265","volume":"37","author":"HC Chung","year":"2019","unstructured":"Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J.Clin.Oncol. 2019;37:1470\u20138.","journal-title":"J.Clin.Oncol."},{"key":"1079_CR88","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1200\/JCO.19.01021","volume":"37","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer. J Clin Oncol. 2019;37:2786\u201394.","journal-title":"J Clin Oncol"},{"key":"1079_CR89","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","volume":"28","author":"N Chaput","year":"2017","unstructured":"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann.Oncol. 2017;28:1368\u201379.","journal-title":"Ann.Oncol."},{"key":"1079_CR90","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.it.2018.09.007","volume":"39","author":"AP Cogdill","year":"2018","unstructured":"Cogdill AP, Gaudreau PO, Arora R, Gopalakrishnan V, Wargo JA. The impact of intratumoral and gastrointestinal microbiota on systemic cancer therapy. Trends Immunol. 2018;39:900\u201320.","journal-title":"Trends Immunol"},{"issue":"7","key":"1079_CR91","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11912-020-00913-y","volume":"22","author":"JL McQuade","year":"2020","unstructured":"McQuade JL, Ologun GO, Arora R, Wargo JA. Gut Microbiome modulation via fecal microbiota transplant to augment immunotherapy in patients with melanoma or other cancers. Curr Oncol Rep. 2020;22(7):74.","journal-title":"Curr Oncol Rep"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-021-01079-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-021-01079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T02:34:25Z","timestamp":1672454065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-021-01079-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1079"],"URL":"https:\/\/doi.org\/10.1007\/s11912-021-01079-x","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"30 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has any potential conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"92"}}